For early-stage NSCLC, lobar resection has been the gold standard since 1995 with publication of the LCSG trial. Given that ...

Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical ...

New research presented at the 2025 Society of Thoracic Surgeons (STS) Annual Meeting reveals that anatomic lung resections, such as lobectomy and segmentectomy, are associated with improved long-term ...

Lung cancer remains the leading cause of cancer-related deaths globally, with cigarette smoking as its primary driver.

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

In the Phase I dose escalation portion, which evaluated the combination in participants with small cell lung cancer, the first patient treated attained partial remission.

New research highlights the promise of a novel stem cell treatment strategy for leptomeningeal brain metastasis (LBM), a ...

BH-30643 is an OMNI-EGFR inhibitor that targets classical, atypical, and compound EGFR mutations and acquired resistance mutations in HER2.

Nuvalent, Inc. shares have fallen approximately 30% after promising updates on its two lead NSCLC candidates rallied the ...

Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.

The Chang Lab at Princeton Chemistry continues in its mission to elucidate the role of metal nutrients in human biology: last ...